Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jul 14, 2022 8:24am
159 Views
Post# 34823430

RE:RE:RE:Early digns of efficacy!!!!

RE:RE:RE:Early digns of efficacy!!!!What's also an amazing stat, from a commercialization angle, is that these patients had an average of 8 previous therapies.  So the resistance angle and the fact nothing else worked, yet this did is an extremely strong and unique therapeutic characteristic.  Really pretty amazing if you were a patient that tried everything, nothing worked --but you took this as one last shot and saw your tumor shrink in half.

qwerty22 wrote:

Just my view but Ali think you need those partial responses. Those are the clearest signs that the drug has anti-tumour activity. Once you have those then the other signs like PSA reduction and prolonged SD add to that. If they have a much larger data set and show very many SD then that is a good stand alone result as well. I think it's about being certain what you have IS anti-tumour activity and tumour shrinkage across multiple tumours in a patient is the clearest indication of that.

 

 

stockman75 wrote: Intersted to hear the medical experts on our boards input on this pr. I am confused a bit on what constitutes efficacy. I have been hearing 30% reduction in tumor size but isn't stabilizing a advanced\progressive disease a great result? Not to mention with less side effects?  So in other words if a drug stops tumor growth with less side effects than current standard is that not a great result?

 

 



<< Previous
Bullboard Posts
Next >>